1st Quarter - Report

BIOMARIN PHARMACEUTICAL INC. for BIOMARIN PHARMACEUTICAL INC.

Firm
Client
Income
—
Expenses
$390,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —
KATHRYN LOWELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1262 (119th)

Medicare/Medicaid MMM

HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1509 (119th)

Tariff (miscellaneous tariff bills) TAR

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.